for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merrimack Pharmaceuticals Inc

MACK.OQ

Latest Trade

5.84USD

Change

0.29(+5.23%)

Volume

41,985

Today's Range

5.50

 - 

5.84

52 Week Range

3.35

 - 

7.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.55
Open
5.50
Volume
41,985
3M AVG Volume
1.41
Today's High
5.84
Today's Low
5.50
52 Week High
7.50
52 Week Low
3.35
Shares Out (MIL)
13.35
Market Cap (MIL)
77.96
Forward P/E
--
Dividend (Yield %)
--

Next Event

Merrimack Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

More

Merrimack Pharmaceuticals Announces Per Share Amount For Previously Declared Special Dividend

Merrimack - JFL Capital Management Has Launched "Unnecessary" Proxy Contest To Replace Entire Board, Effectively Seeking To Acquire Co

JFL Capital Issues Letter To Fellow Merrimack Stockholders

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merrimack Pharmaceuticals Inc

Merrimack Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing novel treatments for cancer by targeting biomarker-defined cancers. Its clinical programs include MM-121 (seribantumab), MM-141 (istiratumab) and MM-310. MM-121 is a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1, or IGF-1, receptor and ErbB3 (HER3) cell surface receptor. MM-310 is an antibody-directed nanotherapeutic that targets the ephrin receptor A2, or EphA2, receptor and contains a novel prodrug of the highly potent chemotherapy docetaxel. The Company’s preclinical programs include MM-161, ATRi, BCL2/BCLxl, TRAIL, Immuno-oncology and STIMULI.

Industry

Biotechnology & Drugs

Contact Info

1 Broadway Fl 14

+1.617.4411000

http://www.merrimackpharma.com

Executive Leadership

Gary L. Crocker

Chairman of the Board, President, Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer

Ellen K. Forest

Head of Human Resources

Daryl C. Drummond

Head of Research

George Demetri

Director

Ulrik B. Nielsen

Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.95
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-87.87
Return on Equity (TTM)
-71.85

Latest News

Merrimack to scrap development of pancreatic cancer treatment

Merrimack Pharmaceuticals Inc said on Monday it would stop developing its experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial.

Merrimack to scrap development of pancreatic cancer treatment

Merrimack Pharmaceuticals Inc said on Monday it would discontinue the development of an experimental treatment for pancreatic cancer after the drug failed to meet the main and secondary goals of a mid-stage trial.

BRIEF-Merrimack Pharmaceuticals Reports Q1 Operating Loss Per Share Of $1.33

* THREE CLINICAL READOUTS EXPECTED IN 2018, INCLUDING DATA FROM TWO RANDOMIZED PHASE 2 STUDIES

BRIEF-Merrimack Provides Business Update And Reports 2017 Financial Results

* MERRIMACK PROVIDES BUSINESS UPDATE AND REPORTS 2017 FINANCIAL RESULTS

BRIEF-Merrimack Strengthens SHERLOC Study Of MM-121 In Non-Small Cell Lung Cancer

* MERRIMACK STRENGTHENS SHERLOC STUDY OF MM-121 IN NON-SMALL CELL LUNG CANCER

BRIEF-Merrimack Says Dosed First Patient In Randomized Phase 2 Clinical Study Of MM-121

* MERRIMACK - DOSED FIRST PATIENT IN RANDOMIZED PHASE 2 CLINICAL STUDY OF MM-121 IN PATIENTS WITH POST-MENOPAUSAL METASTATIC BREAST CANCER

BRIEF-Merrimack Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln

* MERRIMACK PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING Source text :[http://bit.ly/2yGsbJv] Further company coverage:

BRIEF-Merrimack reports Q3 loss per share from continuing operations $0.40

* Merrimack Pharmaceuticals Inc - Qtrly loss per share from continuing operations $0.40

BRIEF-Merrimack receives orphan drug designation for MM-121 for the treatment of type of lung cancer

* Merrimack receives orphan drug designation for MM-121 for the treatment of heregulin positive non-small cell lung cancer

BRIEF-Merrimack commences tender offer for outstanding 4.50 pct convertible senior notes

* Merrimack commences tender offer for any and all of its outstanding 4.50 pct convertible senior notes due 2020

BRIEF-Merrimack announces settlement of convertible note litigation

* Merrimack announces settlement of convertible note litigation

BRIEF-Merrimack announces date of one-for-ten reverse stock split

* Merrimack announces date of one-for-ten reverse stock split

BRIEF-Merrimack Pharmaceuticals names Jean Franchi CFO

* Merrimack Pharmaceuticals Inc - appointment of Jean M. Franchi as chief financial officer, effective August 21, 2017 Source text for Eikon: Further company coverage:

BRIEF-Merrimack reports Q2 loss per share $0.22

* Merrimack - continues to believe cash, cash equivalents as of june 30, potential milestone payments, to be sufficient to fund operations into H2 2019 Source text for Eikon: Further company coverage:

BRIEF-Merrimack appoints Thomas Needham as chief business officer

* Merrimack appoints Thomas Needham as chief business officer Source text for Eikon: Further company coverage:

BRIEF-Merrimack announces completion of enrollment in phase 2 carrie study of mm-141

* Merrimack announces completion of enrollment in phase 2 carrie study of mm-141; data expected in first half of 2018 Source text for Eikon: Further company coverage:

BRIEF-Merrimack reports Q1 loss per share $0.23

* Q1 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S

BRIEF-Merrimack declares $140 mln special dividend

* Merrimack declares $140 mln special dividend in connection with recently completed asset sale

BRIEF-Merrimack completes ONIVYDE sale to Ipsen

* Merrimack launches as new, refocused research & clinical development company with resources to advance prioritized lead pipeline candidates MM-121, MM-141 and MM-310

BRIEF-Merrimack stockholders approve Onivyde, generic Doxil sale to Ipsen

* Merrimack stockholders approve sale of Onivyde and generic version of Doxil to Ipsen for up to $1.025 billion

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up